Clinical trials: Diabetic Retinal Disease
Diabetic Macular Edema, Retina Vein Occlusion
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety, tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels of GB-102 on subjects with Diabetic Macular Edema…
- Trial name
- NCT04085341
- Testing
- GB-102
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Graybug Vision
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
- Trial name
- VOYAGER (NCT05476926)
- Testing
- Faricimab, Port Delivery System with Ranibizumab
- Where
- 299 sites in United States, Argentina and 27 more
- Volunteers
- 6,000 people
- Sponsor
- Hoffmann-La Roche
Diabetic Retinopathy (DR)
Preliminary Assessment of an Automated Tool for Diabetic Retinopathy Screening
This study is being done to evaluate the performance of a software that uses artificial intelligence to analyze photographs of the retina to help detect diabetic retinopathy.
- Trial name
- NCT07404657
- Testing
- automatic analysis of fundus images performed by the software tool based on artificial intelligence
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Centervue SpA
Macular Edema
Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema
This is a proof of mechanism trial to explore the effect of BI 1026706 on the central retinal thickness and to evaluate safety and tolerability of BI 1026706 administered orally for 12 weeks in patients with mild vision…
- Trial name
- NCT02732951
- Testing
- BI 1026706
- Where
- 35 sites in Belgium, France and 6 more
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Ophthalmology, Macular Edema
Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens.
- Conditions
- Ophthalmology, Macular Edema, Macular Degeneration
- Trial name
- POLARIS (NCT01771081)
- Testing
- Ranibizumab (or other DME treatment)
- Where
- 8 sites in France, Germany and 6 more
- Volunteers
- 911 people
- Sponsor
- Bayer
Retinal Vasculitis
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice.
- Trial name
- NCT07105228
- Testing
- aflibercept 2mg
- Where
- United States
- Volunteers
- 290,000 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema
Oxulumis®, Suprachoroidal Drug Administration of Triesence® in Diabetic Macular Edema
The purpose of this clinical investigation is to evaluate the safety and tolerability of using the Oxulumis® microcatheterization device to administer Triesence® to the suprachoroidal space in participants with DME.
- Trial name
- NCT05172401
- Testing
- Oxulumis® suprachoroidal microcatheterization administration of Triesence®
- Sponsor
- Oxular Limited
Diabetic Macular Edema, Branch Retinal Vein Occlusion
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
This is a randomized, double-masked, multicenter, study to evaluate the efficacy, safety, and tolerability of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
- Conditions
- Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
- Trial name
- CLEAN (NCT05127525)
- Testing
- IRX-101, Control
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- iRenix Medical, Inc.
Vitreous Hemorrhage, Diabetic Retinopathy
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
- Trial name
- NCT00198497
- Testing
- Vitrase
- Where
- 58 sites in Australia, Brazil and 7 more
- Volunteers
- 510 people
- Sponsor
- Bausch & Lomb Incorporated
Diabetic Macular Edema, Diabetic Retinopathy
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME).
- Trial name
- NCT05607810
- Testing
- ADVM-022
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Adverum Biotechnologies, Inc.
Age-Related Macular Degeneration, Diabetic Retinopathy
Retinal Imaging Using NOTAL-OCT
Comparison between retinal measurements, done by the Notal-OCT imaging and a commercial OCT (Optical Coherence Tomography)
- Trial name
- NCT03374020
- Testing
- Notal OCT
- Volunteers
- 33 people
- Sponsor
- Notal Vision Ltd.
Diabetic Retinopathy
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
The purpose of this study is to determine the safety and efficacy of Vitreosolve in diabetic retinopathy patients.
- Trial name
- NCT00664183
- Testing
- Vitreosolve
- Where
- 17 sites in United States, India
- Volunteers
- 400 people
- Sponsor
- Vitreoretinal Technologies, Inc.
Diabetic Retinopathy, Diabetic Macular Edema
Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKia
The aim of the study is to find out prevalence and individual stages of Diabetic Retinopathy in patients with type 1 and type 2 DM verified based on complex ophthalmologic measurements in Slovak Republic.
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Diabetes Mellitus
- Trial name
- DIARET SK (NCT02232503)
- Testing
- Studied cohort
- Volunteers
- 4,011 people
- Sponsor
- Novartis Slovakia, s.r.o.
Glaucoma, Age-Related Macular Degeneration
Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images
Eye health is of great importance for quality of life. Some eye diseases can progress and cause permanent damage up to vision loss if they are not treated early.
- Conditions
- Glaucoma, Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
- Trial name
- NCT06213896
- Testing
- Mydriatic Agent, Color Fundus Photography, EyeCheckup v2.0
- Where
- Turkey (Türkiye)
- Volunteers
- 1,528 people, healthy volunteers welcome
- Sponsor
- Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705607
- Testing
- MK-8748, Aflibercept
- Where
- 20 sites in United States
- Volunteers
- 1,104 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).
- Trial name
- ATACAMA (NCT07841899)
- Testing
- OLN324, Aflibercept
- Volunteers
- 450 people
- Sponsor
- Ollin Biosciences, Inc.
Proliferative Diabetic Retinopathy (PDR)
A Study Assessing Efficacy and Safety of OC-10X in the Treatment of PDR
The present study is intended to evaluate the efficacy and safety of topical OC-10X Ophthalmic Suspension in patients diagnosed with proliferative diabetic retinopathy (level 61, 65, 71, or 75). OcuCure Therapeutics, Inc.
- Trial name
- NCT02735369
- Testing
- 2% OC-10X
- Where
- Bangladesh
- Volunteers
- 40 people
- Sponsor
- OcuCure Therapeutics, Inc.
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
- Trial name
- (PENGUIN) (NCT07354477)
- Testing
- QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Qlaris Bio, Inc.
Diabetic Macular Edema
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KESTREL (NCT03481634)
- Testing
- Brolucizumab, Aflibercept
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 566 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc